Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Gilead Sciences, Inc
Femme et Homme Max 99 ans
Gilead Sciences, Inc
MAJ Il y a 5 ans
Filgotinib Alone or in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have Not Yet Started Methotrexate Treatment
The primary objective of this study is to evaluate the effects of filgotinib in combination with MTX versus MTX alone for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured b...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Gilead Sciences, Inc
MAJ Il y a 5 ans
An investigational study to assess the effectiveness and safety of a new investigational drug as a add-on therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate regimen in patients with moderate to severe Rheumatoid Arthritis
To assess the efficacy of GS-5745 versus placebo as an add-on therapy to a TNF inhibitor and methotrexate in subjects with moderate to severe rheumatoid arthritis Rheumatoid Arthritis.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Gilead Sciences, Inc
MAJ Il y a 5 ans
Program to Give the Drug Aztreonam Lysine for Inhalation to Patients with Cystic Fibrosis and infection by the Bacteria Pseudomonas aeruginosa Who Have Limited Treatment Options and are at Risk for Disease Progression
The primary objective of this program is to provide expanded access to aztreonam lysine for inhalation 75 mng prior to its commercial availability to patients with cystic fibrosis and chronic P. aeru...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Gilead Sciences, Inc
MAJ Il y a 5 ans
A study with four oral anti-Hepatitis drugs in patients with Hepatitis C who have already had at least one round of treatment
• To evaluate the antiviral efficacy as measured by SVR of combination therapy with GS-5885, GS-9451, tegobuvir and RBV compared with GS-5885, GS-9451 and tegobuvir or GS-5885, GS-9451 and RBV in trea...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Gilead Sciences, Inc
MAJ Il y a 5 ans
A study to investigate the dose, safety and effectiveness of an experimental drug called elvitegravir for the treatment of HIV infection in children and adolescent patients. Patients must have previously received treatment for their HIV infection, and elvitegravir will be added to their current treatment which must include a ritonavir-boosted protease inhibitor
The primary objectives of this study are: •To evaluate the steady-state PK and confirm the dose of EVG/r in HIV-1 infected, antiretroviral treatment-experienced subjects 4 weeks to less than 18 ye...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Gilead Sciences, Inc
MAJ Il y a 5 ans
An investigational study to assess the safety and effectiveness of a new investgational drug in people with moderately to severely active Ulcerative Colitis
• To evaluate the efficacy of GS-5745 to induce EBS clinical remission at Week 8 (Cohort 1) • To evaluate the efficacy of GS-5745 to maintain EBS clinical remission at Week 52 (Cohort 2) • To evalua...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Gilead Sciences, Inc
MAJ Il y a 5 ans
A Long Term Study to Follow the Safety of a New Treatment in Patients with Ulcerative Colitis
To observe the long-term safety of filgotinib in subjects who have completed or met protocol specified efficacy discontinuation criteria in a prior Gilead-sponsored filgotinib treatment study in UC
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Gilead Sciences, Inc
MAJ Il y a 5 ans
A trial looking at the treatment of SOF/GS-5816 for 12 weeks against the treatment of Sofosbuvir and Ribavirin for 24 weeks in patients with hepatitis C infection
The primary objectives of this study are: * To compare the efficacy of treatment with sofosbuvir (SOF)/GS-5816 fixed dose combination (FDC) for 12 weeks with that of SOF + ribavirin (RBV) for 24 ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Gilead Sciences, Inc
MAJ Il y a 5 ans
A Phase 2, Randomized, Open-Label trial of GS-9256 plus GS-9190 alone and in combination with Ribavirin for 28 days in Treatment Naive Subjects with Chronic Genotype 1 Hepatitis C Virus Infection
The primary objectives of this study are as follows: • To describe the antiviral efficacy of GS 9256 plus GS 9190 alone and in combination with ribavirin (RIBA) against genotype 1 hepatitis C virus (...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Gilead Sciences, Inc
MAJ Il y a 5 ans
A Study to Compare the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Myelofibrosis who were Treated with Ruxolitinib
To determine the efficacy of momelotinib (MMB) versus best available therapy (BAT) in anemic or thrombocytopenic subjects with primary myelofibrosis (PMF), or post-polycythemia vera or post-essential ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
4
5
6
7
8
9
10
11
12
13
Suivant